On April 27, Anvisa announced an immediate suspension of the sale and use of clobutinol-based medications in Brazil due to the risk of severe arrhythmia, determining that the dangers associated with the substance outweigh its therapeutic benefits, particularly given its widespread use in over-the-counter cough syrups often taken without medical supervision. #MedicationSafety #Pharmacovigilance #HealthRegulations #BR #EU #DE #US
Clobutinol: por que a Anvisa proibiu xarope banido em outros países - BBC News Brasil
